Global Influenza Diagnostics Market - 2024-2031

Global Influenza Diagnostics Market - 2024-2031

Global Influenza Diagnostics market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Influenza is caused by the flu virus which causes symptoms such as fever, cough, sore throat, etc. It is usually diagnosed by the symptoms caused or by using rapid diagnostic tests that give results within 30 minutes. PCR is the most common procedure for the detection of the virus to date. Several more tests are available in specific laboratories that help determine specific viruses. RIDTs are used for both children and adults and hence, these types of tests are mostly preferred.

Market Dynamics: Drivers & Restraints

Increasing product launches

Product launches are increased to keep up the demand for influenza diagnostic test kits in diagnostic centers and hospitals. The demand rises during the flu season as the flu cases are observed to jump during the flu season. Hence, the launch of test kits

In June 2022, The Becton, Dickinson & Company's BD MAX Respiratory Viral Panel (RVP), a new molecular diagnostic combination test for SARS-CoV-2, Influenza A+B, and Respiratory Syncytial Virus (RSV), was CE-marked.

In January 2023, 2San launched a dual kit SARS-CoV-2 & Influenza A+B. The OTC kit is launched to help alleviate the pressure on healthcare institutions.

Lack of Skilled Professionals

The lack of qualified and experienced professionals is expected to hamper the market. Skilled workers and healthcare facilities in middle-income countries are limited which hinders the influenza diagnostics market. Diagnostics procedures should be done accurately with all the measures, or else the test kits may show false positive results due to their specificity which can lead to complications such as wrong treatment or no treatment at all in the diseased individual.

Segment Analysisn

The global influenza diagnostics market is segmented based on disease type, test type, end user and region.

RIDT (Rapid Influenza Diagnostic Test) Type is Expected to Dominate Market

RIDT (Rapid Influenza Diagnostic Test) is expected to hold the largest share of the market due to the increasing usage of rapid diagnostic test kits due to their reliability and portability. It is easy to use in homecare settings. FDA authorizations and the launch of rapid diagnostic test kits for the detection of viruses increased due to the demand for the RIDTs.

In February 2023, the FDA authorized the first over-the-counter at-home test, Lucira COVID-19 & Flu home test to detect both influenza and COVID-19 viruses.

In May 2023, Hologic Inc. received the US Drug and Food Administration's 510K clearance for the company’s Panther Fusion SARS-CoV-2/Flu A/B/RSV assay. The assay detects the difference between four respiratory viruses (SARS-CoV 2, Flu A, Flu B, RSV).

Geographical Analysis

North America is Expected to Dominate the Global Market

North America is expected to hold the largest share in the market due to the presence of the highest prevalence in the US. The Centers for Disease Control and Prevention, 2024, estimates that there have been at least 22 million illnesses, 250,000 hospitalizations, and 15,000 deaths from flu so far this season.

Furthermore, according to the Public Health Agency of Canada, From August 2023 to February 2024, 790 laboratory-confirmed influenza outbreaks have been reported in which 69 laboratory-confirmed influenza outbreaks were reported.

Market Segmentation

By Disease Type
• Type A Flu
• Type B Flu
• Type C Flu

By Test Type
• Traditional Diagnostic Test
RIDT (Rapid Influenza Diagnostic Test)
DFAT (Direct Fluorescent Antibody Test)
Others
• Molecular Diagnostic Test
PCR
Others

By End User
• Diagnostic Laboratories
• Hospitals and Clinics
• Research Labs
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In March 2023, Lucira Health launched the first at-home combination COVID-19 & Flu test in the US. The easy-to-use, all-in-one combination test delivers results in 30 minutes or less.
• In April 2023, Danaher subsidiary Cepheid planned to launch multiple new tests for various infectious diseases including tuberculosis and other respiratory infections.
• In August 2023, Abbott Laboratories received US Food and Drug Administration clearance for the ID NOW 2.0 point-of-care diagnostic testing platform.
• In March 2023, MaximBio received a contract from the National Institute of Health (NIH) to develop new rapid test platform for the development of COVID-19 and influenza combination test.

Competitive Landscape

The major global players in the market include Roche Diagnostics Limited, Thermo Fisher Scientific, Inc., Abbott Laboratories, Inc., 3M, Becton, Dickinson, and Company (BD), Hologic, Inc, Danaher Corporation, Biomeurex SA, Siemens Healthineers AG, QIAGEN among others.

Why Purchase the Report?
• To visualize the global influenza diagnostics market segmentation based on disease type, test type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of influenza diagnostics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global influenza diagnostics market report would provide approximately 58 tables, 57 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies